Lee's Pharmaceutical Holdings (FRA:L1PA) Research & Development: €12.2 Mil (TTM As of Dec. 2025)


FRA:L1PA Lee's Pharmaceutical Holdings Ltd FRA:L1PA
74 GF Score
Price €0.11
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings Research & Development?

Lee's Pharmaceutical Holdings FRA:L1PA -4.46% 74 Research & Development is €12.2 Mil as of Dec. 2025. GuruFocus rates FRA:L1PA with a GF Score™ of 74/100 and a GF Value™ of €0.17. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lee's Pharmaceutical Holdings's Research & Development for the six months ended in Dec. 2025 was €7.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €12.2 Mil.

Lee's Pharmaceutical Holdings  (FRA:L1PA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lee's Pharmaceutical Holdings Research & Development Related Terms

Lee's Pharmaceutical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings Research & Development Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.67 20.48 11.37 10.30 12.18

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.64 4.05 6.11 4.60 7.61
FRA:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd FRA:L1PA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €12.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €12.2 Mil mean?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a Research & Development of €12.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Lee's Pharmaceutical Holdings and its competitors.
Is Lee's Pharmaceutical Holdings' Research & Development too high?
Lee's Pharmaceutical Holdings' current Research & Development is €12.2 Mil. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Research & Development compare to ZTS and UTHR?
Lee's Pharmaceutical Holdings' Research & Development of €12.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lee's Pharmaceutical Holdings and its competitors. Lee's Pharmaceutical Holdings's current Research & Development is €12.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current Research & Development of €12.2 Mil. The stock's GF Value™ is €0.17, compared to a current price of €0.11 — trading 37.1% below its estimated fair value. The current Research & Development is €12.2 Mil. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current Research & Development is €12.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.11 is trading 37.1% below its estimated GF Value™ of €0.17.

Key valuation signals for FRA:L1PA:

  • Research & Development: €12.2 Mil
  • GF Value™: €0.17 vs. price of €0.11 (37.1% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for FRA:L1PA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.17
GF Value